Morgan Stanley Reiterates Overweight on Acelyrin, Maintains $29 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit reiterated an Overweight rating on Acelyrin (NASDAQ:SLRN) and maintained a $29 price target.
June 21, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst Vikram Purohit reiterated an Overweight rating on Acelyrin (NASDAQ:SLRN) and maintained a $29 price target.
The reiteration of an Overweight rating by Morgan Stanley analyst Vikram Purohit indicates a positive outlook for Acelyrin's stock. The maintained $29 price target suggests that the analyst believes the stock has potential for growth in the short term. This news is likely to have a positive impact on Acelyrin's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100